ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments

被引：0

作者：

Robado de Lope, L. ^{[1
]}

Serna-Blasco, R. ^{[1
]}

Mediavilla, P. ^{[1
]}

Sanz-Moreno, S. ^{[1
]}

Rodriguez-Festa, A. ^{[1
]}

Gallego-Gil, P. ^{[2
]}

Flores, C. ^{[1
]}

Calvo, V. ^{[2
]}

Collazo-Lorduy, A. ^{[2
]}

Blanco, M. ^{[2
]}

Pena Cabia, S. ^{[3
]}

Diz Tain, P. ^{[4
]}

Garrido Onecha, M. L. ^{[4
]}

Sanchez-Hernandez, A. ^{[5
]}

Sequero Lopez, S. ^{[6
]}

Rogado, J. ^{[7
]}

Coves Sarto, J. ^{[8
]}

Lopez Martin, A. ^{[3
]}

Mielgo, X. ^{[9
]}

Vazquez Estevez, S. ^{[10
]}

Gonzalez-Rumayor, V. ^{[11
]}

Romero, A. ^{[2
]}

Provencio, M. ^{[2
]}

机构：

[1] Inst Invest Sanitaria Puerta Hierro Segovia Arana, Majadahonda, Spain

[2] Hosp Univ Puerta Hierro Majadahonda, Majadahonda, Spain

[3] Hosp Univ Severo Ochoa, Leganes, Spain

[4] Complejo Asistencial Univ Leon, Leon, Spain

[5] Consorcio Hosp Prov Castellon, Castellon De La Plana, Spain

[6] Hosp Univ Clin San Cecilio, Granada, Spain

[7] Hosp Univ Infanta Leonor, Madrid, Spain

[8] Hosp Univ Son Llatzer, Palma de Mallorca, Spain

[9] Hosp Univ Fdn Alcorcon, Alcorcon, Spain

[10] Hosp Univ Lucus Augusti, Lugo, Spain

[11] Atrys Hlth, Barcelona, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

Biomarkers; Immunotherapy; NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.22-16

引用

页码：S252 / S252

页数：1

共 50 条

[21] Discovery of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual screening
Rong Guo
Yuan Zhang
Xiao Li
Xinrui Song
Da Li
Yong Zhao
Journal of Molecular Modeling, 2016, 22
[22] Nrdp1 and ErbB3 expression in non-small cell lung cancer cell lines.
Plate, Janet M.
Iyengar, Ravi M.
Sutton, Parnetta
Bonomi, Philip
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S381 - S381
[23] Homologous recombination deficiency status predicts response to immunotherapy-based treatment in non-small cell lung cancer patients
Gao, Ai
Wang, Xin
Wang, Jing
Zhong, Diansheng
Zhang, Linlin
THORACIC CANCER, 2024, 15 (25) : 1842 - 1853
[24] Discovery of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual screening
Guo, Rong
Zhang, Yuan
Li, Xiao
Song, Xinrui
Li, Da
Zhao, Yong
JOURNAL OF MOLECULAR MODELING, 2016, 22 (06) : 1 - 9
[25] Infrequent ERBB2 mutations in Chinese patients with non-small cell lung cancer
Feng, Shuidong
Ling, Hongyan
Guo, Hui
Tong, Lingling
Hu, Guobin
Liao, Li
Lv, Xueying
Tan, Hongzhuan
Wu, Yimou
JOURNAL OF THORACIC DISEASE, 2014, 6 (05) : 503 - 506
[26] Clinical Characteristics and Outcome of Patients with Non-Small Cell Lung Cancer Harboring BRAF Mutations
Zhang, M.
Wang, H.
Ma, Z.
Zhang, X.
Li, P.
Yan, X.
Zhang, G.
Niu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S695 - S695
[27] Phenotypic Correlates of ERBB2, BRAF and PIK3CA Mutations in Non-Small Cell Lung Cancer.
Zhang, W.
Joshi, V.
Heon, S.
Gandhi, L.
Jackman, D.
Lindeman, N.
Sholl, L.
MODERN PATHOLOGY, 2011, 24 : 430A - 430A
[28] Association of MUC16 mutations with immunotherapy biomarkers in Chinese non-small cell lung cancer patients.
Han, Tao
Guo, Taiyan
You, Xia
He, Qianru
Zhang, Qin
Qi, Chuang
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[29] Immunotherapy in non-small cell lung cancer harbouring driver mutations
Addeo, Alfredo
Passaro, Antonio
Malapelle, Umberto
Banna, Giuseppe Luigi
Subbiah, Vivek
Friedlaender, Alex
CANCER TREATMENT REVIEWS, 2021, 96
[30] Activating ERBB4 mutations in non-small cell lung cancer
Kurppa, Kari J.
Denessiouk, Konstantin
Johnson, Mark S.
Elenius, Klaus
CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →